TNF and rheumatoid arthritis: More than 130,000 RA patients initiating or switching to a b/tsDMARD were included in a large real-world study; it showed that the risk of non-vertebral fractures (hip, humerus, pelvis, and the wrist region) was similar between patients on adalinumab and those on any other TNF-α inhibitor, tocilizumab, abatacept, rituximab, or tofacitinib [96].